Profile data is unavailable for this security.
About the company
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in HKD (TTM)839.66m
- Net income in HKD-506.44m
- Incorporated2015
- Employees1.11k
- LocationInnoCare Pharma LtdBuilding 8, No. 8Life Science Park Road, ZhongguancunLife Science Park, Changping DistrictBeijing 102206ChinaCHN
- Phone+86 1 066609913
- Fax+86 1 060702992
- Websitehttps://www.innocarepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qyuns Therapeutics Co Ltd | 48.31m | -453.64m | 2.89bn | 325.00 | -- | 7.30 | -- | 59.76 | -1.93 | -1.93 | 0.2193 | 1.78 | -- | -- | -- | 145,950.60 | -- | -- | -- | -- | 84.05 | -- | -976.77 | -- | 1.83 | -29.56 | 0.5795 | -- | -- | -- | -70.28 | -- | -- | -- |
| Abbisko Cayman Ltd | 534.81m | -17.42m | 3.02bn | 275.00 | -- | 1.36 | 850.57 | 5.65 | -0.0295 | -0.0295 | 0.8235 | 3.28 | 0.2159 | -- | 65.75 | 2,072,904.00 | -0.7034 | -- | -0.733 | -- | 0.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 405.46k | -402.65m | 3.17bn | 150.00 | -- | 4.91 | -- | 7,816.15 | -1.12 | -1.12 | 0.0011 | 1.73 | -- | -- | -- | 2,796.26 | -- | -- | -- | -- | -- | -- | -99,307.43 | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
| CARsgen Therapeutics Holdings Ltd | 6.82m | -747.33m | 4.17bn | 477.00 | -- | 2.61 | -- | 611.06 | -1.34 | -1.34 | 0.0122 | 2.80 | 0.0027 | -- | 0.302 | 13,214.28 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
| Alphamab Oncology | 275.18m | -231.90m | 4.33bn | 429.00 | -- | 2.48 | -- | 15.74 | -0.2409 | -0.2409 | 0.2858 | 1.82 | 0.1145 | 0.8256 | 13.94 | 632,607.10 | -9.65 | -18.72 | -11.16 | -21.94 | 79.33 | -- | -84.27 | -415.55 | 4.42 | -- | 0.167 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
| Laekna Inc | 0.00 | -317.84m | 4.44bn | 92.00 | -- | 6.10 | -- | -- | -0.8919 | -0.8919 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
| Lepu Biopharma Co Ltd | 220.56m | -78.10m | 5.53bn | 491.00 | -- | 5.62 | 405.74 | 25.05 | -0.0463 | -0.0463 | 0.1325 | 0.5751 | 0.0847 | 1.86 | 1.53 | 514,131.50 | -3.53 | -- | -5.72 | -- | 78.76 | -- | -41.62 | -- | 0.7322 | -2.71 | 0.4621 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
| TYK Medicines Inc | 0.00 | -460.24m | 9.09bn | 144.00 | -- | -- | -- | -- | -1.24 | -1.24 | 0.00 | -3.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -50.25 | -- | -- | -100.00 | -- | -22.97 | -- | -- | -- |
| Keymed Biosciences Inc | 87.82m | -799.16m | 11.58bn | 1.12k | -- | 4.08 | -- | 131.88 | -3.06 | -3.06 | 0.3359 | 10.14 | 0.0207 | 0.3115 | 7.74 | 97,900.21 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Ascentage Pharma Group International | 971.19m | -387.48m | 12.94bn | 574.00 | -- | 15.67 | -- | 13.32 | -1.34 | -1.34 | 3.34 | 2.62 | 0.2998 | 3.49 | 2.19 | 1,665,855.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -8.16 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| InnoCare Pharma Ltd | 839.66m | -506.44m | 14.35bn | 1.11k | -- | 1.67 | -- | 17.10 | -0.2998 | -0.2998 | 0.4971 | 4.22 | 0.0786 | 0.9875 | 3.19 | 771,036.10 | -4.88 | -13.41 | -6.20 | -15.36 | 85.59 | 85.99 | -62.04 | -172.16 | 3.77 | -- | 0.1667 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
Data as of Nov 14 2024. Currency figures normalised to InnoCare Pharma Ltd's reporting currency: Hong Kong Dollar HKD
21.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HHLR Advisors Ltd.as of 31 Dec 2023 | 208.67m | 13.95% |
| GIC Pte Ltd. (Investment Management)as of 11 Apr 2024 | 35.15m | 2.35% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 27.54m | 1.84% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 18.51m | 1.24% |
| RBC Global Asset Management (UK) Ltd.as of 30 Aug 2024 | 7.47m | 0.50% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 6.96m | 0.47% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 6.52m | 0.44% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 6.43m | 0.43% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 6.36m | 0.43% |
| FIL Investment Management (Hong Kong) Ltd.as of 30 Sep 2024 | 5.21m | 0.35% |
More ▼
Data from 30 Jun 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
